SG11202002268XA - Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder - Google Patents

Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder

Info

Publication number
SG11202002268XA
SG11202002268XA SG11202002268XA SG11202002268XA SG11202002268XA SG 11202002268X A SG11202002268X A SG 11202002268XA SG 11202002268X A SG11202002268X A SG 11202002268XA SG 11202002268X A SG11202002268X A SG 11202002268XA SG 11202002268X A SG11202002268X A SG 11202002268XA
Authority
SG
Singapore
Prior art keywords
adrenomedullin
adm
binder
under treatment
monitoring under
Prior art date
Application number
SG11202002268XA
Inventor
Joachim Struck
Andreas Bergmann
Original Assignee
Adrenomed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adrenomed Ag filed Critical Adrenomed Ag
Publication of SG11202002268XA publication Critical patent/SG11202002268XA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7095Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202002268XA 2017-10-18 2018-10-18 Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder SG11202002268XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17197177 2017-10-18
PCT/EP2018/078647 WO2019077082A1 (en) 2017-10-18 2018-10-18 Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder

Publications (1)

Publication Number Publication Date
SG11202002268XA true SG11202002268XA (en) 2020-04-29

Family

ID=60301753

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002268XA SG11202002268XA (en) 2017-10-18 2018-10-18 Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder

Country Status (10)

Country Link
US (1) US20220268761A1 (en)
EP (1) EP3698134A1 (en)
JP (1) JP2021500548A (en)
CN (1) CN111480076A (en)
AU (1) AU2018350861A1 (en)
BR (1) BR112020005682A2 (en)
CA (1) CA3079112A1 (en)
MX (1) MX2020004072A (en)
SG (1) SG11202002268XA (en)
WO (1) WO2019077082A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291688B2 (en) * 2017-09-13 2023-06-15 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング Adrenomezrin precursors as an index for renal replacement therapy in critically ill patients.
EP4021571A1 (en) * 2019-08-30 2022-07-06 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
EP4110811A1 (en) * 2020-02-27 2023-01-04 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
EP4111204A1 (en) * 2020-02-27 2023-01-04 4TEEN4 Pharmaceuticals GmbH Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
WO2022234111A1 (en) 2021-05-07 2022-11-10 Sphingotec Gmbh Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients
WO2023175035A1 (en) * 2022-03-15 2023-09-21 Adrenomed Ag Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
JP2774769B2 (en) 1993-04-26 1998-07-09 賢治 寒川 Adrenomedullin
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
PT1214600E (en) * 1999-09-10 2006-05-31 Us Gov Health & Human Serv DETERMINATION OF PROTEINS FROM LIGACAO TO ADRENOMEDULIN
WO2003020746A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
PT1941867E (en) 2002-06-07 2012-02-16 Dyax Corp Modified kunitz domain polypeptide
DE10316583A1 (en) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Determination of a mid-regional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, as well as immunoassays for carrying out such a determination
WO2004097423A1 (en) 2003-04-25 2004-11-11 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
EP1800131A2 (en) 2004-09-09 2007-06-27 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
DE102006060112A1 (en) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnosis and risk stratification using the new marker CT-proADM
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
RU2650765C1 (en) 2008-11-03 2018-04-17 Молекьюлар Партнерс Аг Binding proteins, inhibiting interaction of vegf-a receptor
US9376477B2 (en) 2009-08-27 2016-06-28 Covagen Ag IL-17 binding compounds and medical uses thereof
WO2011073209A1 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
NZ603562A (en) 2010-06-08 2014-07-25 Pieris Ag Tear lipocalin muteins binding il-4 r alpha
NZ624873A (en) 2011-11-16 2016-07-29 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
ES2751492T3 (en) 2011-11-16 2020-03-31 Adrenomed Ag Anti-adrenomedullin antibody (ADM) or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient to stabilize circulation
MY192113A (en) 2011-11-16 2022-07-28 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
PT2594588E (en) * 2011-11-16 2014-08-28 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
PT2780371T (en) * 2011-11-16 2019-01-30 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
WO2013072510A1 (en) 2011-11-16 2013-05-23 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
CA2907467A1 (en) * 2013-03-20 2014-09-25 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline

Also Published As

Publication number Publication date
EP3698134A1 (en) 2020-08-26
CN111480076A (en) 2020-07-31
AU2018350861A1 (en) 2020-04-09
MX2020004072A (en) 2020-07-28
RU2020115794A3 (en) 2022-01-27
WO2019077082A1 (en) 2019-04-25
BR112020005682A2 (en) 2020-10-20
US20220268761A1 (en) 2022-08-25
JP2021500548A (en) 2021-01-07
RU2020115794A (en) 2021-11-19
CA3079112A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
SG11202002268XA (en) Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
PT3618875T (en) Combination therapy
IL272560A (en) Combination therapy
GB201713914D0 (en) Combination therapy
GB201710360D0 (en) Patient monitoring
GB201713113D0 (en) Combination therapy
GB201706260D0 (en) Combination therapy
GB201706252D0 (en) Combination therapy
GB201706249D0 (en) Combination therapy
GB201706248D0 (en) Combination therapy
GB201706247D0 (en) Combination therapy
GB201706246D0 (en) Combination therapy
GB201706244D0 (en) Combination therapy
GB201706243D0 (en) Combination therapy
GB201706242D0 (en) Combination therapy
GB201706241D0 (en) Combination therapy
GB201706251D0 (en) Combination therapy
GB201706240D0 (en) Combination therapy
GB201706239D0 (en) Combination therapy
GB201706238D0 (en) Combination therapy
GB201706237D0 (en) Combination therapy
GB201706236D0 (en) Combination therapy
GB201706261D0 (en) Combination therapy
GB201706232D0 (en) Combination therapy
GB201706235D0 (en) Combination therapy